The Last of the Meningococcus?
Globally, infectious diseases account for 63% of deaths in children under the age of 4 years, with acute respiratory infection (ARI), diarrhea, measles, malaria, and HIV infection accounting for the greatest proportions of deaths (World Health Organisation, 2000). ARI, for example, is believed to result in 2 million deaths in the under-5 age group and over 3.5 million deaths annually overall. By contrast, the burden of meningococcal infection and mortality is far lower, with only 500,000 cases and about 50,000 deaths per year (Tikhomirov et al., 1997).
KeywordsOuter Membrane Protein Conjugate Vaccine Acute Respiratory Infection Meningococcal Disease Neisseria Meningitidis
Unable to display preview. Download preview PDF.
- Abdel-Hadi, H., Wooldridge, K., Robinson, K., and Ala’Aldeen, D.A. (2000). Investigation of the potential of App as a vaccine candidate. In P. Rice, F. Sparling, and W. Shafer (eds.), Twelfth International Neisseria Conference, HCC Inc, Galveston, Texas.Google Scholar
- Arumugham, R., Fortuna-Nevin, M., Mountzouros, K., Secor, S., Sharma, M., Gibson, B. et al. (1998). Development of Lipooligosaccharide—Protein conjugate vaccines against Group B Neisseria meningitidis. In The Fifth Conference of the International Endotoxin Society, Santa Fe, p. 52.Google Scholar
- Centers for Disease Control and Prevention (2000). Serogroup W-135 meningococcal disease among travelers returning from Saudi Arabia-United States. MMWR 49, 345–346.Google Scholar
- Christodoulides, M., Brooks, J.L., Rattue, E., and Heckeis, J.E. (1998). Immunization with recombinant class 1 outer-membrane protein from Neisseria meningitidis: influence of liposomes and adjuvants on antibody avidity, recognition of native protein and the induction of a bactericidal immune response against meningococci. Microbiology 144, 3027–3037.PubMedCrossRefGoogle Scholar
- Danielson, L. and Mann, E. (1806). The history of a singular and very mortal disease, which lately made its appearance in Medfield. Med. Agric. Reg. 1, 65.Google Scholar
- Danve, B., Lissolo, L., Guinet, F., Boutry, E., Speck, D., Cadoz, M. et al. (1998). Safety and immunogenicity of a Neisseria meningitidisgroup B transferrin binding protein vaccine in adults. In X. Nassif, M.J. Quentin-Millet, and M.-K. Taha (eds.), Eleventh International Pathogenic Neisseria Conference. EDK, Paris, Nice, p. 53.Google Scholar
- Lapeyssonnie, L. (1963). La meningite cerebro-spinale en Afrique. Bull WHO 28, 3–114.Google Scholar
- Rokbi, B., Renauld-Mongenie, G., Mignon, M., Danve, B., Poncet, D., Chabanel, C. et al. (2000). Allelic diversity of the two transferrin binding protein B gene isotypes among a collection of Neisseria meningitidis strains representative of serogroup B disease: implication for the composition of a recombinant TbpB-based vaccine. Infect. Immun. 68, 4938–4947.PubMedCrossRefGoogle Scholar
- Vieusseaux, G. (1805). Memoire sur le maladie qui a regne a Geneve au printemps de 1805. J. Medecine Chirurgie Pharmacie II, 163–165.Google Scholar
- Wang, J.F., Caugant, D.A., Li, X., Hu, X., Poolman, J.T., Crowe, B.A. et al. (1992). Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in the People’s Republic of China. Infect. Immun. 60, 5267–5282.PubMedGoogle Scholar
- Weichselbaum, A. (1887). Ueber die aetiologie der akuten meningitis cerebro-spinalis. Fotschr. Med. 5, 573–583, 620-626.Google Scholar
- Willis, T. (1684). A description of an epidemical feaver in 1661. In T. Dring (ed.), Practice of Physick, Vol. Treatise VIII. London, pp. 46–54.Google Scholar
- World Health Organisation. (2000). WHO report on global surveillance of epidemic-prone infectious diseases. Department of Communicable Disease Surveillance and Response, http://www.who.int/emc-documents/sur-veillance/docs/whocdscsrisr2001.html/Meningitis/Meningitis.htm